ArticleSurgical endoscopy2025
Gender, racial, and socioeconomic disparities in the management and survival of patients with locally advanced esophageal cancer: a SEER-based study.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The global burden of oesophageal cancer from 1990 to 2023 and projections to 2040: a comprehensive analysis of the Global Burden of Disease Study 2023.Journal of global health · 2026Article
- Racial and ethnic disparities in esophageal cancer survival are greatest at curable stages: a population-based study.Cancer causes & control : CCC · 2026Article
- Organ Preservation in Esophageal Cancer: Current Strategies, Challenges, and Future Directions.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer is the sixth most common gastrointestinal cancer in the United States. Treatment for esophageal cancer depends on the extent of the disease but often includes surgery with or without chemoradiation. The aim of this study is to identify possible gender, racial, and socioeconomic disparities in treatment decisions and survival outcomes for patients with locally advanced esophageal cancer.
methodsLocally advanced (stage IIA-IVA) esophageal cancer cases in adults (age ≥ 20 years) diagnosed between 2012 and 2021 were identified from the Surveillance, Epidemiology, and End Results database. Data regarding patient demographics, treatment strategies, and survival outcomes was collected. Multivariate logistic and Cox regression analyses were performed to evaluate the association between various patient characteristics and management patterns and survival.
resultsA total of 10,823 cases were included in this study. Female (OR: 0.71, p < 0.001), Black (OR 0.33, p < 0.001), and Hispanic (OR: 0.75, p < 0.001) patients were less likely to be recommended surgery for their esophageal cancer. Among patients who were recommended surgery, Black race (OR: 0.062, p = 0.006) and Low SES (OR: 0.662, p = 0.007) were associated with a lower likelihood of surgery being performed. Female (OR: 0.74, p = 0.007) and Hispanic (OR 0.64, p = 0.003) patients were less likely to receive neoadjuvant therapy. Female (OR: 0.82, p = 0.040), Black (OR: 0.63, p = 0.018), and Low SES (OR: 0.734, p = 0.008) patients were less likely to receive adjuvant therapy. Female patients had improved OS (HR: 0.88, p < 0.001) and CSS (HR: 0.85, p = 0.003) whereas Black race (OS-HR: 1.32, p < 0.001, CSS-HR: 1.31, p < 0.001) and Low SES (OS-HR: 1.15, p < 0.001, CSS-HR: 1.17, p < 0.001) were associated with worse OS and CSS.
conclusionsSignificant differences in surgical management, administration of neoadjuvant and adjuvant therapy, OS, and CSS exist based on gender, race/ethnicity, and SES. Further research is needed to elucidate and ameliorate the possible causes of these disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.